Market Research Report
Global Anti-CD20 Monoclonal Antibodies (mABs) Market 2022-2026
|Global Anti-CD20 Monoclonal Antibodies (mABs) Market 2022-2026|
Published: March 31, 2022
TechNavio (Infiniti Research Ltd.)
Content info: 120 Pages
Delivery time: 1-2 business days
Technavio has been monitoring the anti-CD20 monoclonal antibodies (mABs) market and it is poised to grow by $ 9.05 bn during 2022-2026 progressing at a CAGR of 9.81% during the forecast period. Our report on the anti-cd20 monoclonal antibodies (mABs) market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increased use of combination therapies, high target affinity and specificity of anti-CD20 mABs, and strong pipeline and recent approvals.
The anti-cd20 monoclonal antibodies (mABs) market analysis includes product segment and geographic landscape.
Technavio's anti-CD20 monoclonal antibodies (mABs) market is segmented as below:
By Geographical Landscape
This study identifies the increasing awareness about therapeutic areas as one of the prime reasons driving the anti-cd20 monoclonal antibodies (mABs) market growth during the next few years. Also, the presence of reimbursement and patient assistance programs, and the development of CD20 bispecific antibodies will lead to sizable demand in the market.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the anti-CD20 monoclonal antibodies (mABs) market covers the following areas:
Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading anti-CD20 monoclonal antibodies (mABs) market vendors that include Acrotech Biopharma, Amgen Inc., AstraZeneca Plc, Celltrion Healthcare Co. Ltd., F. Hoffmann La Roche Ltd., Fosun International Ltd., Genmab AS, IGM Biosciences Inc., JSC BIOCAD, LFB SA, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Spectrum Pharmaceuticals Inc., TG Therapeutics Inc., United BioPharma Inc., and ZHEJIANG HISUN PHARMACEUTICAL Co. Ltd. Also, the anti-CD20 monoclonal antibodies (mABs) market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.